Circulating branched‐chain amino acids and incident heart failure in type 2 diabetes: The Hong Kong Diabetes Register. Issue 3 (19th January 2020)

• Record Type: Journal Article
• Authors: Lim, Lee‐Ling; Lau, Eric S.H.; Fung, Erik; Lee, Heung‐Man; Ma, Ronald C.W.; Tam, Claudia H.T.; Wong, Willy K.K.; Ng, Alex C.W.; Chow, Elaine; Luk, Andrea O.Y.; Jenkins, Alicia; Chan, Juliana C.N.; Kong, Alice P.S.
• Is Part Of: Diabetes/metabolism research and reviews. Volume 36:Issue 3(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-01-19
• Subjects: branched‐chain amino acids -- energy metabolism -- heart failure -- metabolic pathways -- prevention -- type 2 diabetes; Diabetes -- Periodicals; Metabolism -- Periodicals; 616.642
• DOI: 10.1002/dmrr.3253
• Languages: English
• ISSNs: 1520-7552

Abstract

Abstract : Aim: Levels of branched‐chain amino acids (BCAAs, namely, isoleucine, leucine, and valine) are modulated by dietary intake and metabolic/genetic factors. BCAAs are associated with insulin resistance and increased risk of type 2 diabetes (T2D). Although insulin resistance predicts heart failure (HF), the relationship between BCAAs and HF in T2D remains unknown. Methods: In this prospective observational study, we measured BCAAs in fasting serum samples collected at inception from 2139 T2D patients free of cardiovascular‐renal diseases. The study outcome was the first hospitalization for HF. Results: During 29 103 person‐years of follow‐up, 115 primary events occurred (age: 54.8 ± 11.2 years, 48.2% men, median [interquartile range] diabetes duration: 5 years [1‐10]). Patients with incident HF had 5.6% higher serum BCAAs than those without HF (median 639.3 [561.3‐756.3] vs 605.2 [524.8‐708.7] μmol/L; P = .01). Serum BCAAs had a positive linear association with incident HF (per‐SD increase in logarithmically transformed BCAAs: hazard ratio [HR] 1.22 [95% CI 1.07‐1.39]), adjusting for age, sex, and diabetes duration. The HR remained significant after sequential adjustment of risk factors including incident coronary heart disease (1.24, 1.09‐1.41); blood pressure, low‐density lipoprotein cholesterol, and baseline use of related medications (1.31, 1.14‐1.50); HbA1c, waist circumference, triglyceride, and baseline use of related medications (1.28, 1.11‐1.48); albuminuria and estimated glomerular filtration rate (1.28, 1.11‐1.48). The competing risk of death analyses showed similar results. Conclusions: Circulating levels of BCAAs are independently associated with incident HF in patients with T2D. Prospective cohort analysis and randomized trials are needed to evaluate the long‐term safety and efficacy of using different interventions to optimize BCAAs levels in these patients.